Trial Profile

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nirogacestat (Primary) ; PBCAR 269A (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Precision Biosciences

18 Sep 2023 Status changed from completed to discontinued.
05 Jan 2023 Status changed from recruiting to completed.
08 Jun 2022 According to a Precision Biosciences media release, the company has completed DL2 (2.0 X 106 cells/kg) of PBCAR269A plus GSI and is initiating the next cohort at DL3 to further evaluate efficacy and expects to provide an update on this program around year end.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com